LFVN

Lifevantage Corp. 10-Q Summary: Period Ended March 31, 2011

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Lifevantage Corp., a dietary supplement company primarily selling Protandim and LifeVantage TrueScience Anti-Aging Cream via network marketing and direct-to-consumer channels. The reporting period covers the three and nine months ended March 31, 2011. The company is classified as a smaller reporting company.

Key Financial Metrics

Debt and Liquidity: The company holds a revolving line of credit of approximately $433,984. Total liabilities are $22,736,481, driven significantly by derivative liabilities ($17.5M) and accrued commissions ($1.37M). Cash flow from operations for the nine months ended March 31, 2011, was positive at $2,445,151.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 266% for the three months and 239% for the nine months compared to the prior year periods, driven by volume growth in the network marketing channel and new sales in Japan.
• Operating Performance: The company moved from an operating loss of $(1,343,477) to an operating income of $792,263 for the three-month period. For the nine-month period, operating income improved from a loss of $(7,031,622) to income of $1,746,014.
• Net Loss Drivers: Despite operating profitability, the company reported a net loss due to a significant non-cash expense: a $10,090,924 loss on the change in fair value of derivative liabilities for the quarter (and $2,777,953 for the nine months). This contrasts with a gain of $7,345,657 in the prior year nine-month period.
• Expense Trends: Sales and marketing expenses rose significantly ($5.35M vs $1.88M for the quarter) due to higher distributor commissions. General and administrative expenses decreased for the nine-month period ($5.08M vs $6.55M) due to reduced legal and personnel costs.

Guidance, Outlook, and Risks

Management Commentary: Management attributes revenue growth to the expansion of the network marketing channel. They expect gross margins to remain stable around 84%. The company intends to commit approximately 2% of net sales to research and development. Management believes existing cash and future cash flows are sufficient for operations for at least the next 12 months.

Forward-Looking Risks:

• Derivative Volatility: Net income is heavily impacted by the fair value changes of derivative liabilities (warrants and embedded conversion features), which are sensitive to stock price volatility.
• Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding oversight of accounting functions and lack of formal policies. Remediation is planned by June 30, 2011.
• Liquidity and Capital: The company has negative working capital due to the classification of derivative liabilities as short-term. Future financing needs may result in dilution.
• Product Dependence: Significant dependence on a single product (Protandim) and third-party manufacturers.

Unusual Items: An adjustment to the sales return reserve estimate during the quarter increased revenue and reduced net loss by approximately $137,000.

Investor Verification Checklist

• Derivative Liability Valuation: Verify the assumptions (volatility, stock price) used in the Black-Scholes and Lattice models that resulted in a $10M+ quarterly non-cash loss.
• Working Capital Position: Confirm the sustainability of operations given the negative working capital of $(5.45M) and the classification of long-term derivative liabilities as short-term.
• Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting controls by the stated June 30, 2011 deadline.
• Revenue Quality: Assess the sustainability of the 266% revenue growth and the reliance on the network marketing channel.
• Subsequent Events: Note that between April 1 and May 12, 2011, approximately 8.4 million shares were issued via warrant exercises and debt conversions, which may impact future dilution.